If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Director/PDMR Shareholding

3 Nov 2020 14:54

RNS Number : 1387E
Angle PLC
03 November 2020
 

ANGLE plc

("ANGLE" or "the Company")

 

Director/PDMR Dealings

 

 

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, has been notified that the following Directors of the Company purchased ordinary shares of 10 pence each in the Company ("Ordinary Shares") on 2 November 2020:

 

- Ian Griffiths, Finance Director of the Company, purchased 30,000 Ordinary Shares at a price of 44.75 pence per Ordinary Share. Following this purchase Mr. Griffiths is beneficially interested in a total of 703,832 Ordinary Shares, representing approximately 0.41 per cent of the Company's currently issued share capital; and

 

- Garth Selvey, Non-Executive Chairman of the Company, purchased 30,000 Ordinary Shares at a price of 45.00 pence per Ordinary Share. Following this purchase Mr. Selvey is beneficially interested in a total of 50,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's currently issued share capital.

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information ANGLE:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley

ECM - Alice Lane, Sunila de Silva

 

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 

+44 (0) 203 705 9330

 

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

+44 (0) 203 727 1000

+1 212 850 5624

 

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Ian Griffiths

2

Reason for the notification

 

 

a)

Position/status

 

 

Finance Director

b) 

Initial notification /Amendment

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

44.75p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 44.75p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Garth Selvey

2

Reason for the notification

 

 

a)

Position/status 

 

 

Non-Executive Chairman

b) 

Initial notification /Amendment 

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name 

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

45.00p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 45.00p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFBBFLEFBX
Date   Source Headline
28th Jul 20227:00 amRNSNovel insight into metastasis in NSCLC patients
20th Jul 20222:33 pmRNSHolding(s) in Company
20th Jul 20227:00 amRNSNEW STUDY OF PARSORTIX SYSTEM IN NSCLC
19th Jul 202210:00 amRNSDirector/PDMR Shareholding
15th Jul 20227:00 amRNSResults of Capital Raise
14th Jul 20225:24 pmRNSRetail Offer via PrimaryBid
14th Jul 20225:23 pmRNSProposed Placing and Retail Offer
8th Jul 20225:30 pmRNSIssue of Equity
29th Jun 20224:35 pmRNSResult of 2022 Annual General Meeting
27th Jun 20227:00 amRNSSpread of breast cancer accelerates during sleep
23rd Jun 20226:24 pmRNSIssue of Equity
22nd Jun 20227:00 amRNSSecured contract from pharma services customer
16th Jun 20227:00 amRNSPredicting immunotherapy response in SCLC
14th Jun 20227:00 amRNSPotential role of invasive cellular protrusions
30th May 20227:00 amRNSPartnership with major United States urology group
27th May 20227:00 amRNSMolecular characterisation of CTCs
25th May 20224:35 pmRNSPrice Monitoring Extension
25th May 202212:30 pmRNSANGLE receives FDA clearance for Parsortix
20th May 20227:00 amRNSProstate Cancer UK funds new study using Parsortix
28th Apr 20227:00 amRNSPreliminary Results
20th Apr 20227:00 amRNSNotice of Preliminary Results and Webcast
14th Apr 20227:00 amRNSPoster on Parsortix system presented at AACR 2022
1st Apr 20227:00 amRNSIdentifying drug targets in cancer metastasis
29th Mar 20227:00 amRNSRapid information on patient response to therapies
25th Mar 20227:00 amRNSIdentifying therapeutic targets in TNBC patients
15th Mar 20227:00 amRNSUpdate on laboratory accreditation
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20226:29 pmRNSHolding(s) in Company
18th Feb 20225:13 pmRNSIssue of Equity
21st Jan 20227:00 amRNSPotential in immunotherapy treatment selection
17th Jan 20227:00 amRNSConcordance of Parsortix with tissue biopsy
13th Jan 20227:00 amRNSUpdate on lab accreditation and ovarian study
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.